N-[[[(1S)-1-Carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid

ZJ43 (723331-20-2) is potent inhibitor of glutamate carboxypeptidases II (Ki = 0.8 nM) and III (Ki = 23 nM).1It potently (IC50= 2.4 nM) inhibited the ability of glutamate carboxypeptidase II to hydrolyze the neurotransmitter N-acetylaspartylglutamate (NAAG) resulting in an increase in synaptic levels of group II mGluRs. Peripherally administered ZJ43 increased the activation of mGluR3 by NAAG released from peripheral sensory neurites resulting in analgesia.2,3ZJ43 has also shown efficacy in other inflammatory pain models.4,5

Potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (K i values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC 50 = 2.4 nM) . Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.

as a potent inhibitor of glutamate carboxypeptidase ii and iii (gcp ii and iii) with kivalues of 0.8 and 23 nm respectively, zj-43 inhibited the hydrolysis of naag via indirect interactions with nmda or metabotropic glutamate receptors [1].

intravenous injection of zj-43 coiuld suppress both phases of the agitation behaviour induced by paw formalin injection in the rat neuropathic pain model. moreover, intravenous administration of zj-43 attenuated the level of mechanical allodynia induced by the nerve ligation. these effects of zj-43 in both the formalin test and the partial sciatic nerve ligation model were completely antagonized by pretreatment with ly-341495, which was a highly selective group ii mglur antagonist [1].

2.4 nm

Store at -20°C

[1] RAFAL T. OLSZEWSKI. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR[J]. Journal of Neurochemistry, 2004, 89 4: 876-885. DOI:10.1111/j.1471-4159.2004.02358.x
[2] TATSUO YAMAMOTO. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model[J]. European Journal of Neuroscience, 2004, 20 2: 483-494. DOI:10.1111/j.1460-9568.2004.03504.x
[3] TATSUO YAMAMOTO. Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats[J]. European Journal of Neuroscience, 2007, 25 1: 147-158. DOI:10.1111/j.1460-9568.2006.05272.x
[4] TATSUO YAMAMOTO. Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain.[J]. Molecular Pain, 2008: 31. DOI:10.1186/1744-8069-4-31
[5] TAKAHIRO NONAKA. A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.[J]. Molecular Pain, 2017, 13: 1744806917697008. DOI:10.1177/1744806917697008